United States: Neon Therapeutics Enters License Agreement With Broad Institute, Dana-Farber And Mass General
Last Updated: December 17 2015

On December 9, 2015, Neon Therapeutics, an immuno-oncology company developing neoantigen-based therapeutic vaccines and T cell therapies to treat cancer, announced that the company has entered into a license agreement with the Broad Institute, Dana-Farber Cancer Institute and Massachusetts General Hospital for technology to be utilized in Neon Therapeutics' pipeline.

Neon Therapeutics was represented by WilmerHale in this transaction, with Partners Richard Hoffman and Michael Bevilacqua, and Associate Ritu Gupta.

View Neon Therapeutics' press release for more information.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Some comments from our readers…
“The articles are extremely timely and highly applicable”
“I often find critical information not available elsewhere”
“As in-house counsel, Mondaq’s service is of great value”

Press Releases from this Firm
Recent Content from this Firm
By Michael Connor, H. David Gold, Sarah Judkins, Andrew L. Spielman
By Lester Ross, Tingting Liu
By H. David Gold, Rachel Jacobson, Heidi K. Ruckriegle
By Joseph Mueller, Thomas Saunders, Leslie Pearlson
By WilmerHale
By Robert D. Burke, A. William Caporizzo, Julie Hogan Rodgers, Meghan Walsh
By WilmerHale
By Jamie Gorelick, William McLucas, Bruce M. Berman, Danielle Conley, Tania Faransso
By Ambassador Charlene Barshefsky, Naboth van den Broek, David Ross, Patrick J. McLain, David Horn
By David Gammell
Font Size: